These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 20030248)

  • 1. [Molecular-targeted therapies for spinal and bulbar muscular atrophy].
    Katsuno M; Banno H; Suzuki K; Adachi H; Tanaka F; Sobue G
    Rinsho Shinkeigaku; 2009 Nov; 49(11):917-20. PubMed ID: 20030248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy.
    Katsuno M; Banno H; Suzuki K; Adachi H; Tanaka F; Sobue G
    Arch Neurol; 2012 Apr; 69(4):436-40. PubMed ID: 22158719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular-targeted therapy for spinal and bulbar muscular atrophy (SBMA)].
    Sobue G
    Rinsho Shinkeigaku; 2010 Nov; 50(11):839-41. PubMed ID: 21921465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and molecular mechanisms of spinal and bulbar muscular atrophy (SBMA).
    Katsuno M; Banno H; Suzuki K; Adachi H; Tanaka F; Sobue G
    Adv Exp Med Biol; 2010; 685():64-74. PubMed ID: 20687495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Disease-modifying therapy for spinal and bulbar muscular atrophy (SBMA)].
    Suzuki K; Banno H; Katsuno M; Adachi H; Tanaka F; Sobue G
    Brain Nerve; 2012 Mar; 64(3):237-44. PubMed ID: 22402717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanisms and Therapeutics for SBMA/Kennedy's Disease.
    Arnold FJ; Merry DE
    Neurotherapeutics; 2019 Oct; 16(4):928-947. PubMed ID: 31686397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. X-Linked Spinal and Bulbar Muscular Atrophy: From Clinical Genetic Features and Molecular Pathology to Mechanisms Underlying Disease Toxicity.
    Cortes CJ; La Spada AR
    Adv Exp Med Biol; 2018; 1049():103-133. PubMed ID: 29427100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA).
    Katsuno M; Tanaka F; Adachi H; Banno H; Suzuki K; Watanabe H; Sobue G
    Prog Neurobiol; 2012 Dec; 99(3):246-56. PubMed ID: 22609045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.
    Katsuno M; Adachi H; Tanaka F; Sobue G
    J Mol Med (Berl); 2004 May; 82(5):298-307. PubMed ID: 15133611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro and In Vivo Modeling of Spinal and Bulbar Muscular Atrophy.
    Pennuto M; Basso M
    J Mol Neurosci; 2016 Mar; 58(3):365-73. PubMed ID: 26614347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA).
    Banno H; Katsuno M; Suzuki K; Tanaka F; Sobue G
    Cell Tissue Res; 2012 Jul; 349(1):313-20. PubMed ID: 22476656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular-targeted therapy for neurodegenerative diseases].
    Sobue G
    Rinsho Shinkeigaku; 2009 Nov; 49(11):747-9. PubMed ID: 20030200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy.
    Renier KJ; Troxell-Smith SM; Johansen JA; Katsuno M; Adachi H; Sobue G; Chua JP; Sun Kim H; Lieberman AP; Breedlove SM; Jordan CL
    Endocrinology; 2014 Jul; 155(7):2624-34. PubMed ID: 24742193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kennedy's disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease.
    Breza M; Koutsis G
    J Neurol; 2019 Mar; 266(3):565-573. PubMed ID: 30006721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA).
    Hashizume A; Fischbeck KH; Pennuto M; Fratta P; Katsuno M
    J Neurol Neurosurg Psychiatry; 2020 Oct; 91(10):1085-1091. PubMed ID: 32934110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasomal and autophagic degradative activities in spinal and bulbar muscular atrophy.
    Rusmini P; Bolzoni E; Crippa V; Onesto E; Sau D; Galbiati M; Piccolella M; Poletti A
    Neurobiol Dis; 2010 Nov; 40(2):361-9. PubMed ID: 20621188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the androgen receptor CAG repeat polymorphism in prostate cancer, and spinal and bulbar muscular atrophy.
    Kumar R; Atamna H; Zakharov MN; Bhasin S; Khan SH; Jasuja R
    Life Sci; 2011 Mar; 88(13-14):565-71. PubMed ID: 21284948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathology and therapeutic intervention in spinal and bulbar muscular atrophy.
    Banno H; Katsuno M; Suzuki K; Tanaka F; Sobue G
    Int J Mol Sci; 2009 Mar; 10(3):1000-12. PubMed ID: 19399234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of androgen receptor polyQ chain elongation in Kennedy's disease and use of natural osmolytes as potential therapeutic targets.
    Kumar R
    IUBMB Life; 2012 Nov; 64(11):879-84. PubMed ID: 23024039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of treatment of spinal and bulbar muscular atrophy.
    Tanaka F; Katsuno M; Banno H; Suzuki K; Adachi H; Sobue G
    Neural Plast; 2012; 2012():369284. PubMed ID: 22720173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.